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BACKGROUND: The multidrug resistance (MDR) proteins are present in a majority of human tumours. Their activity is important to
understand the chemotherapeutic failure. A search for MDR-reversing compounds was conducted among various Betti-base
derivatives of tylosin.
METHODS: Here, we evaluate the in vitro and in vivo P-glycoprotein (P-gp)-modulating activity of the most promising compound
N-tylosil-1-a-amino-(3-bromophenyl)-methyl-2-naphthol (TBN) using human MDR1 gene-transfected and parental L5178 mouse
lymphoma cell lines.
RESULTS: In vitro experiments showed that TBN dramatically increased the P-gp-mediated cellular uptake of the fluorescent substrate
rhodamine 123. Similarly, TBN was found to act as a very potent enhancer of the cytotoxicity of doxorubicin on the resistant cell line.
We also provide in vivo evidence using DBA/2 mice in support for an increased tumoural accumulation of doxorubicin, without
affecting its tissue distribution, resulting in an enhanced antitumoural effect.
CONCLUSION: Our results suggest that TBN is a potent modulator of the P-gp membrane pump and that the compound could be of
clinical relevance to improve the efficacy of chemotherapy in MDR cancers.
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As tumour cells may acquire cross-resistance to many structurally
and functionally unrelated anticancer drugs, development of
multidrug resistance (MDR) is one of the main reasons for
treatment failure in the chemotherapy of malignant tumours.
A common cause of MDR is expression of the MDR gene (mdr1)
and its protein product P-glycoprotein (P-gp), a membrane pump
endowed with a drug-efflux activity. Consequently, by means of
inhibition of the P-gp pump, thus reversing cellular resistance, one
should be able to restore the inherent potency of antitumour
agents. In the past decades, a quest for effective MDR reverting
drugs has emerged, and numerous potent P-gp inhibitors have
been tested so far, including verapamil, cyclosporine analogues
(Krishna and Mayer, 2000) and the anthranilamide derivative
tariquidar (Roe et al, 1999). Unfortunately, to date, there is no
resistance modifier in medical practice; however, encouraging
clinical trials were reported for tariquidar (Pusztai et al, 2005) and
another specific P-gp inhibitor ONT-093 (Chi et al, 2005).
To find novel effective compounds with MDR reversal activity,
more than a hundred compounds containing a carbo- and/or
heterocyclic skeleton and various functional groups, prepared in the
recent years in the Institute of Pharmaceutical Chemistry, University
of Szeged, were tested. As a result of the outcome of our screening, a
large set of Betti-base derivatives was prepared and each of the
compounds further examined for their in vitro P-gp inhibitory
effects. Of all compounds investigated, the most promising was
N-tylosil-1-a-amino-(3-bromophenyl)-methyl-2-naphthol (TBN), a
1-a-amino-(3-bromophenyl)-methyl-2-naphthol derivative of tylosin
(see Figure 1). Tylosin is a compound belonging to the macrolides,
a class of antibiotics, which are clinically used and are considered to
be safe with minimal side effects. Betti-bases can easily be prepared
by the hydrolysis of the condensation product obtained from the
corresponding aromatic aldehyde with 2-naphthol in the presence of
ammonia (Betti, 1941; Szatma ´ri et al, 2003; Szatma ´ri and Fu ¨lo ¨p,
2004). Betti-bases featuring a free primary amine readily react with
the aldehyde group present in tylosin. Under reductive amination
conditions, the Schiff base formed is further stabilised by reduction
(Omura, 1984).
This study was performed to fully appreciate the in vitro and
in vivo MDR reversal activity of the compound. We show that
TBN, and much less so the individual Betti-base and tylosin
moiety, is able to dramatically increase the cellular uptake of the
fluorescent P-gp substrate rhodamine 123 in human MDR1 gene-
transfected mouse T-cell lymphoma drug-resistant cell line L5178Y
and to fully reverse the cellular resistance against doxorubicin. We
also provide in vivo evidence using DBA/2 mice bearing syngeneic
L5178Y tumours in support for an increased tumoural accumula-
tion of doxorubicin, without affecting its tissue distribution,
resulting in an enhanced antitumoural effect. Our results, there-
fore, suggest that TBN could be of clinical relevance to improve the
efficacy of chemotherapy in MDR cancers.
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Chemistry
Experimental section Melting points were determined on a Kofler
micro-melting apparatus and are uncorrected. Elemental analyses
were performed with a Perkin-Elmer 2400 CHNS elemental
analyser (Perkin-Elmer, Waltham, MA, USA). Merck Kieselgel
60F254 plates were used for thin layer chromatography.
Materials TBN was prepared (see Figure 1) according to
Szatma ´ri et al (2003) by stirring a solution of tylosin tartrate
(Sigma, St Louis, MO, USA) (0.20g, 0.18mmol), the Betti-base
(1-a-amino-(3-bromophenyl)-methyl-2-naphthol) (0.2mmol) and
formic acid (0.01g, 0.22mmol) in ethanol (20ml) at room
temperature for 24h. After removal of the solvent under reduced
pressure, the residue was taken up in aqueous Na2CO3 solution
(10ml) and extracted three times with chloroform (10ml). The
organic layer was collected, dried with sodium sulphate and then
the solvent was evaporated. The crude product was crystallised
with n-hexane (5ml) and recrystallised from n-hexane–diisopro-
pyl ether (5:2).
The yield was 0.18g (81%) and melting point 160–1621C.
Analytically calculated for C63H91BrN2O17 was C, 61.60; H, 7.47; N,
2.28 and the results were C, 61.72; H, 7.41; N, 2.30.
Bioassays
Chemicals Doxorubicin HCl was purchased from Teva Pharma
(Wilrijk, Belgium) and Aventis Pharma (Brussels, Belgium),
respectively. Other compounds used were rhodamine 123 (Sigma),
verapamil (EGIS, Hungarian Pharmaceutical Company, Budapest,
Hungary), MTT (thiazolyl blue, Sigma), perchloric acid (Sigma-
Aldrich, Steinheim, Germany) for acidified water (pH 2.05) and
sodium dodecyl sulphate (SDS) (Sigma). Water was purified by the
Milli-Q system (Millipore, Milford, USA).
Cell culture and animals L5178 mouse T-cell lymphoma cells
were transfected with pHa MDR1/A retrovirus, as described earlier
(Cornwell et al, 1987). The MDR1-expressing cell lines were
selected by culturing the cells in the presence of 60ngml
–1
colchicine. The parent L5178 mouse T-cell lymphoma cells and the
transfected subline were cultured in McCoy’s 5A medium
supplemented with 10% heat-inactivated horse serum L-glutamine
and antibiotics. The cell lines were incubated in a humified
atmosphere (5% CO2, 95% air) at 371C. The DBA/2 inbred mice
(female, 5–7 weeks old) and Balb/c mice (female, 5–7 weeks old)
were obtained from Charles River Laboratory (France). After an
experiment, the animals were killed by cervical dislocation.
All aspects of the animal experiment and husbandry were carried
out in compliance with national and European regulations and
were approved by the Animal Care and Use Committee of
K.U.Leuven.
Flow cytometric assay of rhodamine 123 cellular accumulation
Parental or transfected L5178 cells were adjusted to a density of
2 10
6 per ml, resuspended in serum-free medium and distributed
as 0.5-ml aliquots into microvials. Compounds at different
concentrations (verapamil (control), TBN, the corresponding
Betti-base moiety and tylosin) or vehicle were added and the
samples incubated for 10min at room temperature. Next, 10ml
(5.2mM final concentration) of a solution of rhodamine 123 (Sigma)
was added and the cells were incubated for a further 20min at 371C,
washed twice and resuspended in 0.5ml PBS for analysis. The
fluorescence of the cell population was measured with a Beckton
Dickinson FACScan flow cytometer. The percentage mean fluores-
cence intensity was calculated for the parental and transfected
L5178 cells, and compared with the untreated cells. A fluorescence
activity ratio (FAR) was calculated from the following equation on
the basis of the measured fluorescence values:
FAR ¼
Transfected cells;treated=Transfected cells;control
Parentalcells;treated=Parentalcells;control
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Figure 1 Reaction scheme. (A) Tylosin, (B) Betti-base, (C) TBN (N-tylosil-1-a-amino-(3-bromophenyl)-methyl-2-naphthol). r.t., room temperature.
Table 1 FARs of the compounds calculated on the basis of the
measured fluorescence values (see Materials and methods)
Samples Concentration (lm) FAR ± s.d.
Verapamil 22 10±3.2
Betti-base 3.5 10±5.1
35 8±1.7
Tylosin 3.5 1±0.0
35 5±7.5
TBN 3.5 105±8.5
35 94±25.5
Abbreviations: FAR¼fluorescence activity ratio; TBN¼N-tylosil-1-a-amino-
(3-bromophenyl)-methyl-2-naphthol. Non-resistant (parental cells) and human
MDR1 gene-transfected L5178 mouse lymphoma cells were treated with rhodamine
123 and the individual compounds for 20min at 371C. The fluorescence of the cell
population was then measured with a flow cytometer. Mean and s.d. values were
calculated from at least three independent experiments.
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cells were treated with different concentrations of TBN, the
corresponding Betti-base, tylosin or doxorubicin, or combina-
tions of different concentrations of doxorubicin with two fixed
concentrations of TBN, the Betti-base or tylosin, or vehicle
to investigate the antiproliferative effect of the compounds or
their combination on the cells. First, the compounds were diluted
in a volume of 100ml medium in each well, then 1 10
4 cells in
50ml of medium were added. The culture plates were further
incubated at 371C for 72h. At the end of the incubation
period, 20ml of MTT solution (5mgml
–1) was added to each
well. After incubation at 371C for 4h, 100ml of SDS solution
(10%) was added and the plates were further incubated at
371C overnight. The relative cell density was determined by
measuring the optical density (OD) at 550nm (reference 630nm)
with a Dynatech MRX vertical beam ELISA reader. Inhibition
of cell growth (as a percentage) was determined according to
the formula:
100  
OD sample   OD medium control
OD cell control   OD medium control

 100
Short-term cellular accumulation and cytotoxicity of doxo-
rubicin Parental or transfected L5178 cells were plated using
24-well plates (4 10
6 cells per 1.5ml per well) in serum-free
medium; TBN (10mM) was added (or not) 30min before exposing
the cells to 40mM doxorubicin at 371C for 1h. For the toxicity
assay, the cell suspensions were centrifuged on 4500r.p.m. for
Table 2 IC values calculated for the investigated compounds
Transfected cells Parental cells
Compounds IC10lM±s.d. IC50lM±s.d. IC90lM±s.d. IC10lM±s.d. IC50lM±s.d. IC90lM±s.d.
Betti-base 5.0±4.4 40.2±4.5 75.3±5.2 0.5±0.1 4.1±0.2 35.3±8.3
Tylosin 133.1±52.8 410.0±31.8 885.4±51.0 76.1±49.4 561.3±66.4 1046.3±182.4
TBN 11.1±9.2 41.4±6.8 55.2±2.5 9.4±4.4 40.3±2.7 71.3±1.3
Doxorubicin 0.02±0.01 1.8±0.5 14.6±1.7 0.005±0.001 0.022±0.2 0.359±0.05
Abbreviation: TBN¼N-tylosil-1-a-amino-(3-bromophenyl)-methyl-2-naphthol. Non-resistant (parental cells) and human MDR1 gene-transfected (transfected cells) L5178
mouse lymphoma cells were treated with different concentrations of the compounds or vehicle and incubated in cell culture plates at 371C for 72h. At the end of the incubation
period, the relative cell density was determined using an MTT assay and optical density reading. From the inhibitory curves obtained, corresponding IC10,I C 50 and IC90 values
were calculated. Mean and s.d. values were calculated from at least three independent experiments.
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Figure 2 (A) Doxorubicin accumulation (in mgml
–1, assuming an average volume of 3ml per 10
6 cells) in non-resistant (parental cells) and human MDR1
gene-transfected (transfected cells) L5178 mouse lymphoma cells. Cells were exposed to 40mM doxorubicin for 1h (with or without 10mM TBN), after
which they were extracted and the amount of doxorubicin quantified by LC. The values are mean ± s.d. of three independent experiments. (B) Effect of
40mM doxorubicin for 1h (with or without 10mM TBN) on the proliferation of the different cells. After treatment, cells were washed and cultured for 48h at
371C using 96-well plates. The values are mean ± s.d. of three independent experiments (each conducted in triplicate). Significant differences between
means, as specified by capped lines, are indicated by ***Po0.0001. ns, not significant.
Table 3 IC50 values and AF calculated for doxorubicin, when combined
with the Betti-base, tylosin or TBN
Transfected cells Parental cells
IC50lm ± s.e. AF IC50lm ± s.e. AF
Betti-base IC10 0.2±0.3 9.2 0.01±0.2 1.7
Betti-base IC10/10 2.5±0.5 0.7 0.02±0.2 1.0
Tylosin IC10 0.2±0.1 7.4 0.02±0.3 1.1
Tylosin IC10/10 0.2±0.1 7.4 0.02±0.2 0.6
TBN IC10 0.01±0.1 134.1 0.008±0.1 2.8
TBN IC10/10 0.2±0.1 10.5 0.05±0.02 0.4
Abbreviations: AF¼antiproliferative factors; TBN¼N-tylosil-1-a-amino-(3-bromo-
phenyl)-methyl-2-naphthol. Non-resistant (parental cells) and human MDR1 gene-
transfected (transfected cells) L5178 mouse lymphoma cells were treated in cell
culture plates at 371C for 72h with different concentrations of doxorubicin, and
co-incubated with the IC10 or a 10-fold lower concentration (IC10/10) of the Betti-
base, tylosin or TBN. At the end of the incubation period, the relative cell density was
determined using an MTT assay and optical density reading. From the inhibitory
curves obtained, corresponding IC50 values were calculated. AF were determined
by dividing the IC50 value of doxorubicin in the absence of the Betti-base, tylosin or
TBN by the IC50 value of doxorubicin in their presence. Mean and s.e. values were
calculated from at least four independent experiments.
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cultured for 48h at 371C using 96-well plates (10
5 cell per 0.15ml
per well) in serum-supplemented medium. Cell proliferation was
evaluated by the above-mentioned MTT test. For the accumulation
assay, another part of the cell suspensions was washed twice with
ice-cold PBS. After resuspending in water, cells were extracted and
the amount of doxorubicin quantified by liquid chromatography
(LC) (see further). The results were calculated assuming a mean
volume of 3ml per 10
6 cells (Lin et al, 1991).
Tumoural accumulation of doxorubicin The DBA/2 mice were
anesthetised and injected subcutaneously with 4 10
6 cells of the
parental or transfected L5178 cells. Tumours were allowed to grow
to ca. 0.5cm diameter, after which the animals were treated once
with TBN (or vehicle) administered either intraperitoneally (i.p.)
(10 or 50mgkg
–1) or intravenously (i.v.) (10mgkg
–1) through
a lateral tail vein, and doxorubicin (i.p. or i.v., 10mgkg
–1)o r
vehicle. Tumours were excised 24h later and stored at  201C until
extraction and LC analysis.
In vivo pharmacokinetic study of doxorubicin The TBN
(50mgkg
–1) or vehicle was administered i.p. 3h before the i.v.
administration of doxorubicin (10mgkg
–1) or vehicle to Balb/c
mice. At various time points (30min, 1, 5, 24 and 48h) after
doxorubicin injection, mice were killed. Plasma and tissue samples
from liver, kidneys and heart were collected and stored at  201C
until extraction and LC analysis.
Sample extraction and doxorubicin quantification The amount of
doxorubicin in plasma and tissues was quantified as described by
van Asperen et al (1998). The LC system consisted of a Hitachi
Elite LaChrom L-2130 solvent delivery module and a Hitachi Elite
LaChrom L-2480 fluorescence detector (Hitachi High-Techno-
logies Corporation Tokyo, Japan). The LiChroCART 250–4
analytical column packed with 5mm Purospher STAR material
(Merck, Darmstadt, Germany) was protected by a LiChrospher
guard column (4 4mm) (Merck, Darmstadt, Germany). The
mobile phase was composed of acidified water (pH 2.05)/
acetonitrile/tetrahydrofuran (64:35:1, v/v/v) and was degassed
by ultrasonication. A flow rate of 0.8mlmin
–1 was used. The
column eluent was monitored fluorimetrically at 460nm (ex) and
550nm (em).
In vivo efficacy test The ability of TBN to potentiate the
antitumour activity of doxorubicin was evaluated using
the MDR1 gene-transfected L5178 xenografts. When the tumour
size reached a diameter of ca. 0.5cm, the animals were randomised
and treated every second day with TBN (10 or 50mgkg
–1)o r
vehicle that was administered i.p. 3h before doxorubicin (i.p., 2 or
4mgkg
–1). Animals were weighed and the tumours measured
every second day. The tumour volume (TV) was calculated from
the following equation (according to Zalatnai and Molnar, 2006):
TV ¼
width
2 length
2
Animals were killed and tumours were excised and weighed on
12 day.
Statistics Analysis of variance or Student’s t-test using Prism 5
(Graphpad software) was performed to determine the significance of
differences between the means. Significance was accepted at Po0.05.
RESULTS
Flow cytometric assay of rhodamine 123 accumulation
in tumour cells
The TBN and its two building blocks, tylosin and the correspond-
ing Betti-base, were examined in a short-term rhodamine 123
(R123) accumulation assay for their P-gp inhibitory effect, using
both the parental and human MDR1 gene-transfected L5178 mouse
lymphoma cells. The results are displayed in Table 1. Compared
with untreated resistant cells, the presence of TBN resulted in a ca.
100-fold higher R123 accumulation in mouse lymphoma cells, even
at a low concentration, whereas the tylosin and the Betti-base
showed only limited effect. In these short-term experiments, no
signs of toxicity or cell damage were observed.
In vitro antiproliferative effects
Using an antiproliferative assay, the cytotoxic effects of the three
compounds and doxorubicin on the parental and transfected
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Figure 3 Accumulation of doxorubicin (in mgg
–1) in tumours consisting
of parental or transfected L5178 cells growing subcutaneously in DBA/2
mice. Mice were treated with doxorubicin (A:1 0 m g k g
–1, i.p.;
B:1 0 m g k g
–1, i.v.). (A) TBN (10mgkg
–1) was administered (or not)
i.p. 3h or i.v. 1h before doxorubicin treatment; (B) TBN (50mgkg
–1) was
administered (or not) i.p. 3h before doxorubicin treatment. Tumours were
excised 24h later, stored at  201C until extraction and LC analysis. The
values are mean ± s.d. of seven independent experiments. Significant
differences between means, as specified by capped lines, are indicated
by **Po0.001. ns, not significant.
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corresponding IC10,I C 50 and IC90 values were calculated (Table 2).
The Betti-base and TBN displayed a somewhat similar anti-
proliferative profile, at least in case of the transfected cells,
whereas the two cell lines used exhibited a much lower sensitivity
towards tylosin. Of interest, depending on the IC value under
investigation, the parental cells were about four-fold (IC10), 40-fold
(IC90) or 80-fold (IC50) more sensitive towards doxorubicin as
compared with the transfected L5178 cells.
Consequently, the ability of TBN to reverse the resistance
against doxorubicin of the transfected cells was investigated and its
was used at its IC10 concentration, that is 9.4mM and a 10-fold
lower concentration (IC10/10), that is 0.94mM, in combination with
different concentrations of doxorubicin. At both concentrations,
TBN enhanced significantly the cytotoxic effect of doxorubicin on
the resistant L5178 cells (Table 3). Similar experiments showed
much less effects for the Betti-base and tylosin.
Short-term in vitro accumulation and cytotoxicity of
doxorubicin
To test whether the increased cytotoxicity observed in the earlier
experiments correlates with an enhanced intracellular concentra-
tion of doxorubicin, we exposed the parental and transfected
L5178 tumour cells to 40mM doxorubicin for 1h in the presence
or absence of TBN (10mM). The amount of doxorubicin that
accumulated in non-resistant L5178 cells was about three- to four-
fold the one recovered from resistant cells. Treatment by TBN was
able to restore the amount of doxorubicin accumulating in the
resistant cells (Figure 2A). Altogether, we found evidence that
a correlation exist between the accumulation of doxorubicin and
its toxic effects (Figure 2B) on L5178 cells in vitro, at least after
a short exposure of the cells to doxorubicin.
In vivo doxorubicin accumulation
When doxorubicin (10mgkg
–1) was injected i.p., low levels of
doxorubicin were detected in MDR1-expressing L5178 tumours
(Figure 3A). In these conditions, TBN (10mgkg
–1) was able
to enhance the tumoural accumulation of doxorubicin when
it was administered i.v. 1h or i.p. 3h before doxorubicin to the
levels recovered from non-resistant L5178 tumours. However,
when TBN and doxorubicin were simultaneously injected, no
increase of the doxorubicin could be observed (data not shown).
After administering 10mgkg
–1 doxorubicin i.v., the recovered
amount of drug was more than the double as compared with
the one obtained after similar i.p. injections (Figure 3B). As can
be seen, also in this case, TBN (i.p., 50mgkg
–1) was able to
restore the doxorubicin accumulation in MDR1-expressing L5178
tumours.
In vivo pharmacokinetic study of doxorubicin
Administration of TBN at a dose of 50mgkg
–1 (i.p.) 3h before
doxorubicin (10mgkg
–1, i.v.) in Balb/c mice had no signif-
icant effect on the pharmacokinetic behaviour of doxorubicin
(Figure 4).
In vivo efficacy evaluation
The ability of TBN to enhance the antitumoural efficacy of
doxorubicin was tested on DBA/2 mice bearing MDR1-expressing
and non-transfected, sensitive L5178 tumours (Figure 5). The
growth rate of the MDR1-expressing L5178 tumours was
significantly reduced by administration of TBN (10mgkg
–1)3 h
before doxorubicin (4mgkg
–1) as compared with doxorubicin
alone (Figure 5A). In contrast, the other treatment regimen (TBN:
50mgkg
–1, doxorubicin: 2mgkg
–1) was much less effective
(Figure 5B). A similar outcome was obtained by measuring the
weight of the tumours excised on day 12 (Figure 6). Obviously,
doxorubicin alone had an antitumoural effect on sensitive L5178
tumours (Figure 5C). The combination of 50mgkg
–1 TBN and
doxorubicin resulted in a slight decrease in body mass of mice as a
function of time compared with the condition in which only
doxorubicin was used. This was not the case when 10mgkg
–1TBN
was used (Figure 5).
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Figure 4 Tissue distribution of doxorubicin. Balb/c mice were injected with doxorubicin alone i.v. (10mgkg
–1) or with TBN (50mgkg
–1) i.p. 3h before
doxorubicin i.v. (10mgkg
–1). At various times after doxorubicin injection (30min, 1, 5, 24 and 48h) three to five mice were killed. Plasma and tissue samples
from liver, kidneys and heart were collected and stored at  201C until extraction and liquid chromatography analysis. The values are mean ± s.e.
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sDISCUSSION
This study shows that TBN is a potent modulator of P-gp-mediated
MDR, as shown by using both in vitro and in vivo a human MDR1
gene-transfected mouse lymphoma cell line and its parental
doxorubicin-sensitive counterpart. Conversely, by using an in vitro
accumulation and antiproliferative assay, we were able to reveal
that the building blocks of TBN, that is tylosin and the corres-
ponding Betti-base, display rather weak effects on P-gp-mediated
MDR. As rhodamine 123 and doxorubicin used in these tests,
respectively, are well-known substrates of P-gp (Mankhetkorn et al,
1999; Marbeuf-Gueye et al, 2000; Loo and Clarke, 2002; Wang
et al, 2006), our data show that by introducing a nitrogen atom and
some aromatic rings, macrolide antibiotics can easily be converted
from weak into potent MDR-reversing compounds. This finding
also suggests that the molecular weight and lipophilicity of
compounds have a crucial function in P-gp substrate specificity
and/or inhibition, as earlier reported by Didziapetris et al (2003).
The Betti-modification endows TBN with higher cytotoxicity as
compared with tylosin. In contrast to the Betti-base itself, this
cytotoxic effect does not differ between parental and transfected
L5178 cells, suggesting that the compound is not a substrate of the
P-gp membrane pump. On the other hand, the acute toxicity of
TBN seems to be low, as only 50mgkg
–1, but not 10mgkg
–1,
given i.p. every second day over a period of 12 days resulted in
limited weight loss. In this study, we further observed in vivo that
even a single administration of a low dose of TBN (10mgkg
–1)
restored completely the ability of tumours consisting of transfected
L5178 cells to accumulate doxorubicin to the level of the parental
doxorubicin-sensitive cell line. A certain time interval, for example
1h after i.v. or 3h after i.p. injections, between the administration
of TBN and doxorubicin was required, as simultaneous
co-administration of the compounds did not result in increased
doxorubicin levels in resistant L5178 tumours. Consequently, we
could also prove that TBN significantly increased the antitumour
activity of doxorubicin on doxorubicin-resistant L5178 tumours.
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Figure 5 Antitumour activity of doxorubicin in the presence or absence of TBN. Tumours consisted of parental (C) or transfected L5178 cells (A, B)
growing subcutaneously in DBA/2 mice. When the tumour size reached 0.5cm diameter, the animals were randomised and treated every second day. The
TBN (A:1 0m gk g
–1; B:5 0m gk g
–1) was administered (or not) i.p. 3h before doxorubicin (A: 4mgkg
–1; B: 2mgkg
–1, C: 4mgkg
–1) was injected i.p.
Animals were weighed every second day and the experiments were terminated on 12th day. The values represent mean ± s.e. of five to eight animals per
group. Significant differences on the individual days between means of the ‘doxorubicin’ arm and the ‘doxorubicin ± TBN’ arm (A, B) or ‘control’ arm and
the ‘doxorubicin’ arm (C) are indicated by *Po0.01, **Po0.001 and ***Po0.0001. No indication implies no significant difference between the means.
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sFor instance, whereas 4mgkg
–1 doxorubicin given i.p. every
second day did not result in any antitumoural effect on resistant
L5178 tumours over a period of 12 days, the combination with
10mgkg
–1 TBN dramatically reduced the TV by 58% on day 12.
This is in line with the results obtained when 4mgkg
–1
doxorubicin was given to mice bearing sensitive L5178 tumours:
in this case a 46% reduction of TV was achieved. This data again
imply that TBN is able to restore in vivo completely the sensitivity
of transfected L5178 tumours towards doxorubicin.
Studies with mdr1a and mdr1b knock out mice have suggested
that P-gp is not essential for basic physiological functions.
However, as the P-gp membrane pump is expressed at the renal
tubule and biliary and intestinal lumen, P-gp modulation can
reduce the clearance of anticancer drugs, and by doing so,
dramatically increase their toxicity (Sikic et al, 1997; Schinkel,
1998). Some inhibitors such as PSC 833 (Sikic et al, 1997) and
biricodar (Rowinsky et al, 1998) have shown major pharmaco-
kinetic interactions with anticancer drugs, whereas others such as
XR9576 (Mistry et al, 2001) and LY 335979 (Dantzig et al, 1996)
did not. Here, we show that TBN at the highest dose studied
(50mgkg
–1) did not affect the clearance of doxorubicin from
heart, liver, kidney and plasma, and hence the observed increased
levels of the antitumoural compound in resistant L5178 tumours
are not attributable to a sustained presence of the compound into
the circulation.
In conclusion, the present observations state that the MDR
reversal activity of the antibiotic tylosin can be dramatically
increased by introducing a Betti-base in the basic macrolide
structure. Our results indicate that TBN, the Betti-base derivative
of tylosin, can chemosensitise resistant tumour cells to doxo-
rubicin in vitro and in vivo by increasing the accumulation of
doxorubicin. The co-administration of a low but efficacious
dose of the compound with doxorubicin is well tolerated in mice.
The lack of any influence of TBN on the pharmacokinetics of
doxorubicin is a major argument for the specificity of the effect
observed. Our results suggest that TBN is a potent modulator
of the P-gp membrane pump and that the compound could be
of clinical relevance to improve the efficacy of chemotherapy in
MDR cancers. Nevertheless, future studies are needed to further
characterise the interaction between TBN and P-gp, and possibly
other ATP-binding cassette transporters, and long-term toxicity
aspects of the compound.
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Figure 6 Effect of doxorubicin on the tumour weight in the presence or
absence of TBN. Tumours consisted of transfected L5178 cells growing
subcutaneously in DBA/2 mice. When the tumour size reached 0.5cm
diameter, the animals were randomised and treated every second day. The
TBN (10 or 50mgkg
–1) was administered i.p. 3h before doxorubicin (4 or
2mgkg
–1, respectively) was injected i.p. On day 12, animals were killed
and tumours were excised and weighed. The values represent mean ± s.e.
of five to eight animals per group. Significant differences between means, as
specified by capped lines, are indicated by **Po0.001. ns, not significant.
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